CGM for Healthy People: Useful N=1 Toy, or Marketing in a Sticker?

A CGM does not measure your blood sugar. It is a tiny thread sensor in the fat under your upper-arm skin. It reads glucose in the interstitial fluid (the watery space between your cells) and estimates your blood value from there. That fluid runs 5 to 15 minutes behind. And with a typical MARD (the average error against a lab value) of 8 to 14 percent, most readings land within 20 percent of your blood value, while some miss by more.

The lag grows when your sugar is rising or dropping fast. So a CGM curve can look quite different from a finger-prick taken in the very same second. The sensor is not wrong. It is just reading a slightly delayed version of the story.

How accurate is it? Researchers report this as MARD, which is basically the average percentage by which the sensor misses the lab value (lower is better). A 2024 head-to-head test put two sensors on 56 adults with diabetes (33 with type 1, 23 with type 2) and checked them against a lab reference. The FreeStyle Libre 3 came in at 8.9 percent, the Dexcom G7 at 13.6 percent ^[7]. Worth knowing: Abbott, the maker of the Libre, paid for that study. In healthy people with normal glucose the accuracy may differ. The companies' own approval trials report different figures, often closer to 8 to 9 percent for both, because who you test, how you check, and which glucose range you look at all change the result.

What this means in your hand: MARD is an average miss, not a limit. Most readings land within 20 percent of your blood value: about 9 in 10 for the Libre 3 and 8 in 10 for the G7 in one 2024 study ^[7]. That also means about 1 in 12 Libre 3 readings and about 1 in 5 Dexcom G7 readings were off by more than 20 mg/dL (or 20 percent) ^[7]. Stick two sensors on the same arm and they will disagree, sometimes by 15 mg/dL. That is the technology working as designed, not a broken sensor. One more 2026 caveat: Abbott has flagged some FreeStyle Libre 3 and Libre 3 Plus sensors that may show falsely low readings. If you wear one, check its serial number at freestylecheck.com.

Which devices show up in DACH? Abbott FreeStyle Libre 3 Plus, Dexcom G7, and Dexcom ONE+ are all CE-marked and mostly prescribed for diabetes. On the consumer side you have Abbott Lingo (FDA-cleared in June 2024, sold in the UK and US) and Dexcom Stelo (FDA-cleared in March 2024, sold in the US). Neither is officially sold in DACH. Platforms like Hello Inside (a Vienna start-up), Levels Health (US) and NutriSense (US) pair someone else's sensor with their own coaching app.

Short version: a healthy person sits around 99 mg/dL on average, with quick little bumps to 130 to 140 mg/dL after meals. That number is not a guess. It comes from a 2019 study in the Journal of Clinical Endocrinology and Metabolism. Researchers put blinded CGMs (a Dexcom G6 with the screen hidden) on 153 healthy people without diabetes, 96 adults and 57 children and teens aged 7 to 80, at 12 US centres and tracked them for about 8 days ^[3]. Here is what they saw:

• Average glucose over 24 hours: 99 mg/dL (SD 7).
• Time spent between 70 and 140 mg/dL: a median of 96 percent (the middle half of people landed between 93 and 98 percent).
• Time above 180 mg/dL: basically none.

Adults aged 60 and over averaged a bit higher, around 104 mg/dL, and spent noticeably more time above 140 mg/dL than younger adults. But even healthy young people crossed 140 now and then, almost always just briefly after a meal.

What a CGM shows in healthy people	Typical value
24-hour average	98 to 99 mg/dL, about 104 mg/dL over age 60 [3]
Time between 70 and 140 mg/dL	median 96 percent [3]
Time above 140 mg/dL	median 2.1 percent, about 30 minutes a day [3]
Time below 70 mg/dL	median 1.1 percent, about 15 minutes a day [3]
Swings (coefficient of variation)	about 17 percent [3]
Time between 70 and 180 mg/dL, adults around 58	97.8 percent on average [10]
Time above 140 mg/dL, adults around 58	about 12 percent, roughly 3 hours a day [10]

A bigger 2025 community study in the same journal followed a much larger group of adults without diabetes (560 of them with normal glucose) ^[10]. It confirmed that time above 180 mg/dL is rare in people with normal glucose, but it painted a looser picture for middle-aged adults. Average time in range (70 to 180 mg/dL) was 97.8 percent (SD 4.9). Time above 180 mg/dL was negligible for most.

Here is the nuance though. Time above 180 mg/dL is uncommon, but it is not zero. About 20 percent of these normal-glucose adults still spent more than 2 percent of the day above 180 mg/dL. In the tighter window, 70 to 140 mg/dL, the average was about 87 percent. And these normal-glucose adults (average age 58) spent roughly 3 hours a day above 140 mg/dL.

Now the paper everyone quotes online: a 2018 PLOS Biology study that gave us the word "glucotypes". A Stanford team ran CGMs on 57 adults and fed standardized test meals to a subset of them ^[2]. Even with the exact same meal, people's glucose responses varied wildly. Three clear patterns showed up (low, moderate, and severe swings), including in people whose HbA1c (a three-month average blood-sugar marker) was normal. This is where the popular line "everyone responds differently to food" actually comes from. The claim is true, and the data are genuinely interesting. They also come from a 57-person observational study with no longevity or heart outcomes attached to it. A European team later questioned whether glucotypes hold up in other groups, and whether they mostly just reflect average glucose ^[12].

What about official targets? The ATTD international consensus from 2019 in Diabetes Care sets clinical CGM targets, but only for people who have diabetes ^[1]. For healthy adults, nobody has agreed on what "time in range" should even mean or whether it matters. The ADA Standards of Care 2025 (Section 7) describe over-the-counter CGMs as meant for people with prediabetes or diabetes who are not on insulin, and make no recommendation for healthy people ^[4]. The 2026 update now states plainly that anyone, including people without diabetes, can buy these sensors to see how food and exercise move their glucose. It still makes no clinical recommendation for healthy users ^[5].

In two weeks a CGM can show you three real things: how specific meals move your own curve, what a bad night of sleep does to your glucose the next morning, and how alcohol, stress, illness, and exercise shift your line. It cannot diagnose anything, prove a spike is harmful, or predict your 20-year heart risk. Treat the two weeks as a one-person experiment, not a verdict.

A CGM can genuinely teach you a few things about your own body. The obvious one is how different meals move your own curve. White bread on its own versus the same bread after a walk, or eaten alongside some protein and fat, will give you different rises. That is your data, not a population average. You can also watch what a bad night of sleep does to your glucose the next morning. In a study of 953 healthy adults wearing CGMs, worse sleep efficiency and a later bedtime went along with higher blood sugar after breakfast the next morning ^[11]. And you can see exactly what alcohol, a cold, stress, and a hard workout do to your line.

The list of things a CGM cannot tell you is much longer. It cannot diagnose prediabetes or diabetes. Those need a fasting glucose test, an OGTT (a standard test where you drink sugar and they measure how fast you clear it), and an HbA1c, not a bunch of CGM peaks. It cannot tell you a spike to 150 mg/dL is bad. It cannot tell you whether your spike pattern predicts heart disease or death 20 years from now, because no randomized trial in healthy adults has ever asked that question. And it definitely cannot tell you to go low-carb, keto, carnivore, or start intermittent fasting. Those are clinical calls, and they belong with a Hausarzt (your GP) or a registered dietitian.

Think of it this way: a CGM is a structured experiment on a single person, you. Use it to spot patterns and bring the weird ones to a doctor, and it can be useful. Treat it like a daily report card, and it tends to hand you anxiety, food avoidance, and overcorrection that is its own kind of unhealthy.

Right at the point where it claims to improve health. No randomized trial in healthy adults shows that wearing a CGM lowers heart risk or extends life. Yet brands stretch one real finding (your post-meal response varies from person to person) into longevity claims. The 2024 FDA clearance of over-the-counter consumer CGMs is a permission to sell, not proof of benefit.

These companies all start from that real finding:

• Abbott (Lingo)
• Dexcom (Stelo)
• Levels Health (US only, not available in DACH)
• NutriSense (US)
• Zoe (UK). It used a CGM in the past but dropped it for a questionnaire-based glucose-prediction model. An optional gut-microbiome test remains.
• Hello Inside (Austria)
• Veri (Finland)
• Glucura and Una Health (Germany)

Your glucose response after a meal really does vary from person to person and from food to food. Then they stretch that into claims about metabolic health and longevity that the evidence just does not back yet. It is a classic case of a strong signal dragging a much weaker outcome story behind it.

In 2024 the FDA cleared two of the first over-the-counter consumer CGMs: Dexcom Stelo in March and Abbott Lingo later that year. Both sell without a prescription to adults 18 and up who are not on insulin. But that is a permission slip, not proof. It means the devices are safe enough to sell off the shelf, not that wearing one makes a healthy person healthier.

A 2024 narrative review in Diabetic Medicine looked specifically at people without diabetes wearing CGMs and came back cautious. In plain terms: the evidence that it helps is thin and all over the place, some commercial claims risk misleading people, and side effects like cutting out too many foods and getting anxious deserve real attention. The authors went so far as to call for stricter rules on consumer marketing ^[6].

A 2021 review in BMJ Open Diabetes Research and Care shows that glucose swings track with heart outcomes in type 2 diabetes ^[9]. That review says nothing about healthy people. Stretching the finding onto them is an inference, not something the data show.

Where the data stand: there are simply no long-term randomized trials showing that CGM use in healthy people improves hard endpoints like mortality, new diabetes cases, or heart attacks and strokes. What we have is observational data on patterns ^{[2, 3, 10]} and plausibility arguments from diabetes research. Neither is the same as a proven longevity benefit.

The downsides are not zero. The anchoring effect is real: someone sees a 145 mg/dL spike after porridge, panics, switches to bacon and eggs, and never questions the assumption again. The orthorexia risk is real too, where the obsession with "clean" eating becomes the problem. Case reports link CGM use to disordered eating in people who were already anxious. And the cost adds up fast. A healthy self-payer in DACH spends about EUR 71 to 90 per sensor. The current FreeStyle Libre 3 Plus lasts 15 days and costs EUR 70.60 on Abbott's own self-pay subscription (September 2026), more for a single box or at a pharmacy. Wear one nonstop and that is about EUR 1,700 to 2,300 a year (roughly 24 to 25 sensors). None of it gets reimbursed by statutory (GKV) or private insurance without a coded diabetes diagnosis (ICD-10 codes E10 or E11, meaning type 1 or type 2 diabetes).

Put together: in a healthy person, a CGM is an interesting biomarker, not a proven longevity intervention. Treat it like a sauna habit you are trying out. Use it, see if it actually changes anything you care about, then decide whether about EUR 1,700 to 2,300 a year buys you more than a single private blood panel with HbA1c, fasting insulin, and an OGTT.

Two routes work in 2026, both self-paid. You can buy FreeStyle Libre 3 Plus sensors without a prescription from Abbott's German web shop (EUR 70.60 per 15-day sensor on the self-pay subscription, September 2026) or at an Apotheke (pharmacy). Or you can use Hello Inside, a Vienna app that ships Libre sensors to healthy users in Germany, Austria and Switzerland for EUR 90 each. Lingo and Stelo are not officially sold here. No insurer pays without a diabetes diagnosis. Prices move, so check them the day you buy. Here is the neutral lay of the land.

Option	Where	Wear time	Price (Sept 2026)	For healthy people in DACH?
FreeStyle Libre 3 Plus	Abbott web shop, Apotheke	15 days	EUR 70.60 per sensor on subscription, more single	Yes, self-pay
Hello Inside (Libre sensor plus app)	helloinside.com	14 days	EUR 90 per sensor	Yes, built for people without diabetes
Abbott Lingo	US, UK	14 days	from USD 54 for two weeks (US)	No official sale
Dexcom Stelo	US only	15 days	USD 89 a month (US)	No official sale
Private blood panel (HbA1c, fasting insulin, ApoB, hs-CRP)	Lab or GP	once a year	EUR 150 to 350	Yes

Abbott FreeStyle Libre is the most widely used diabetes CGM in Germany and Austria. It sits on the Hilfsmittelverzeichnis (the official list of reimbursable medical aids), and statutory health insurance pays for it only if you have insulin-requiring diabetes on intensified insulin therapy. No diagnosis? You can still buy sensors as a Selbstzahler (self-payer). Since October 2024, Abbott Germany sells only the Libre 3 Plus to self-payers, at about EUR 71 to 90 per 15-day sensor (EUR 70.60 on Abbott's own subscription, more for a single box or at a pharmacy). In Switzerland, the basic insurance (Grundversicherung) covers CGM through KLV/MiGeL (the Swiss list of covered medical aids) only for diagnosed diabetes that meets specific clinical criteria. Wellness use by healthy people is not covered.

Abbott Lingo is the consumer version. It launched over the counter in the United Kingdom and the United States in 2024. As of September 2026 there is no official DACH or wider EU rollout, so calling its DACH availability "patchy" is being generous. Anyone in DACH using Lingo got it through a cross-border parcel or a US/UK reshipper. There is no CE-MDR route (the EU medical-device approval) to sell it directly to consumers in DE, AT, or CH.

Dexcom G7 is prescription-only in DACH and meant for managing diabetes. Dexcom Stelo, the US over-the-counter product from 2024, is still sold only in the US as of September 2026. Check the maker's regional pages for the current status.

Hello Inside is a Vienna-based start-up selling a CGM-plus-coaching service, aimed mostly at women interested in metabolic health. The sensor underneath is an Abbott FreeStyle Libre. Hello Inside is the coaching layer on top, at EUR 90 per sensor, so roughly EUR 20 more than Abbott's own subscription. Whether that is worth it depends on how much you value the app's hand-holding. We mention it neutrally, not as a recommendation.

One thing people mix up constantly: the DiGA-approved digital health apps in Germany (Una Health, Glucura) are reimbursed for diagnosed type-2 diabetes, not for healthy users. Do not assume that coverage carries over to wellness use.

So for a healthy adult in DACH 2026, the realistic self-payer path looks like this: buy two Libre 3 Plus sensors (about EUR 140 to 180 for a month), use the maker's free app, and add a coaching service if you want one. No reimbursement applies.

The research validates blood markers, not CGM curves. For metabolism the proven set is fasting glucose, HbA1c, fasting insulin with HOMA-IR, and a 75 g OGTT; for heart and longevity it is ApoB, Lp(a), triglycerides, hs-CRP, and HDL-C. A once-a-year private panel covering these costs EUR 150 to 350 in DACH, a fraction of a year of CGM sensors, and every marker has decades of outcome data behind it.

If what you actually want is an evidence-based metabolic check-in, the proven markers are boring, cheap, and very well studied. Fasting glucose plus HbA1c gives you a reliable read on your average blood sugar over the past 8 to 12 weeks. Fasting insulin, and the HOMA-IR score you calculate from it (a simple math formula that estimates insulin resistance), is the best non-invasive stand-in for insulin resistance your Hausarzt (GP) can order. And then there is the 75 g OGTT. You drink a fixed sugar load, and the lab measures glucose and insulin at 0, 60, and 120 minutes. It is still the best test we have for catching impaired glucose handling and early high insulin before your HbA1c even budges.

For heart and longevity-adjacent markers, the proven set is short: ApoB (a count of harmful cholesterol particles) and Lp(a) (a genetic risk marker you only need to test once), triglycerides, hs-CRP (a sensitive inflammation marker), and HDL-C. Pair those with blood pressure, waist size, and resting heart rate, and every one has decades of large cohort data linking it to heart disease and death. For ApoB and blood pressure, randomized trials also show that lowering them prevents heart attacks and strokes. Glucose swings from a CGM have none of that evidence in healthy adults.

Let us make it concrete. In DACH 2026, a private self-payer blood panel with HbA1c, fasting glucose, fasting insulin, a lipid panel including ApoB, hs-CRP, and basic thyroid markers costs EUR 150 to 350, once a year. A year of CGM sensors as a healthy self-payer costs about EUR 1,700 to 2,300. The blood panel has decades of outcome data behind it. The CGM has the Stanford glucotypes paper ^[2] and a healthy-cohort baseline of 153 people ^[3]. Both can be useful. Only one is actually validated.

The sensible move for a curious, longevity-minded adult: one structured two-week experiment to see what your own meals and habits do to your curve, knowing the result is data, not destiny. Then go back to the proven markers and a doctor who actually reads them, and check first what your health insurance already covers before paying out of pocket.